Pathological response to neoadjuvant 5-FU, oxaliplatin, and docetaxel (FLOT) versus epirubicin, cisplatin, and 5-FU (ECF) in patients with locally advanced, resectable gastric/esophagogastric junction (EGJ) cancer: Data from the phase II part of the FLOT4 phase III study of the AIO

被引：1
|
作者：
Pauligk, Claudia
Tannapfel, Andrea
Meiler, Johannes
Luley, Kim Barbara
Kopp, Hans-Georg
Homann, Nils
Hofheinz, Ralf Dieter
Schmalenberg, Harald
Probst, Stephan
Haag, Georg Martin
Egger, Matthias
Behringer, Dirk M.
Stoehlmacher, Jan
Prasnikar, Nicole
Block, Andreas
Trojan, Jorg
Koenigsmann, Michael
Schmiegel, Wolff
Jaeger, Elke
Al-Batran, Salah-Eddin
机构：
[1] Univ Canc Ctr, Krankenhaus Nordwest, Frankfurt, Germany
[2] Ruhr Univ Bochum, Inst Pathol, Bochum, Germany
[3] Univ Hosp Essen, West German Canc Ctr, Dept Med Oncol, Essen, Germany
[4] UKSH Campus Luebeck, Lubeck, Germany
[5] Univ Hosp, Med Ctr 2, Tubingen, Germany
[6] Acad Teaching Hosp Wolfsburg, Dept Internal Med 2, Wolfsburg, Germany
[7] Univ Med Ctr Mannheim, Dept Hematol & Med Oncol, Mannheim, Germany
[8] Univ Klinikum Jena, Jena, Germany
[9] Klinikum Bielefeld, Bielefeld, Germany
[10] Univ Heidelberg Hosp, Natl Ctr Tumor Dis, Dept Med Oncol, Heidelberg, Germany
[11] Ortenau Klinikum Lahr, Lahr, Germany
[12] Augusta Kranken Anstalt, Bochum, Germany
[13] Univ Klinikum Carl Gustav Carus, Dresden, Germany
[14] Klinikum Ludwigsburg, Ludwigsburg, Germany
[15] Univ Hosp Hamburg Eppendorf, Hamburg, Germany
[16] Goethe Univ Frankfurt, D-60054 Frankfurt, Germany
[17] MediProjekt, Hannover, Germany
[18] Ruhr Univ Bochum, Knappschaftskrankenhaus, Dept Internal Med, Bochum, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.4016
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4016
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Pazopanib and 5-FU/oxaliplatin as first-line treatment in advanced gastric cancer: PaFLO, a randomized phase II study from the AIO (Arbeitsgemeinschaft Internistische Onkologie)
    Thuss-Patience, Peter C.
    Al-Batran, Salah-Eddin
    Siveke, Jens T.
    Homann, Nils
    Malfertheiner, Peter
    Glaeser, Dietrich
    Stein, Alexander
    Tamm, Ingo
    Daum, Severin
    Potenberg, Jochem
    Florschuetz, Axel
    Vogel, Arndt
    Ridwelski, Karsten
    Ritgen, Matthias
    Geissler, Michael
    Schmalenberg, Harald
    Schlattmann, Peter
    Lorenz, Mario
    Breithaupt, Kirstin
    Pichlmeier, Uwe
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [42] Modified Epirubicin, cisplatin, and 5-FU regimen as first-line chemotherapy in metastatic gastric or gastroesophageal junction adenocarcinoma: A Phase II study
    Babu, K. Govind
    Chaudhuri, Tamojit
    Lakshmaiah, K. C.
    Dasappa, Lokanatha
    Jacob, Linu Abraham
    Babu, M. C. Suresh
    Rudresha, A. H.
    Lokesh, K. N.
    Rajeev, L. K.
    SOUTH ASIAN JOURNAL OF CANCER, 2019, 8 (02) : 85 - 87
  • [43] A randomized phase III study comparing 2-weekly docetaxel, cisplatin and 5-FU (bDCF) with cisplatin and 5-FU (CF) in patients with metastatic or recurrent esophageal cancer: JCOG1314 (MIRACLE).
    Tsushima, Takahiro
    Hironaka, Shuichi
    Tsubosa, Yasuhiro
    Kato, Ken
    Nomura, Motoo
    Hara, Hiroki
    Kitagawa, Yuko
    Koyanagi, Kazuo
    Kajiwara, Takeshi
    Takegawa, Naoki
    Matsubara, Hisahiro
    Baba, Hideo
    Morita, Masaru
    Masuzawa, Toru
    Hasegawa, Hiroko
    Kojima, Takashi
    Machida, Ryunosuke
    Sasaki, Keita
    Takeuchi, Hiroya
    Kadowaki, Shigenori
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 322 - 322
  • [44] Gefitinib in combination with 5-fluorouracil (5-FU)/folinic acid and irinotecan in patients with 5-FU/oxaliplatin-refractory colorectal cancer: A phase I/II study of the arbeitsgemeinschaft fur internistische onkologie (AIO)
    Hofheinz, Ralf-Dieter
    Kubicka, Stefan
    Wollert, Joerg
    Arnold, Dirk
    Hochhaus, Andreas
    ONKOLOGIE, 2006, 29 (12): : 563 - 567
  • [45] Phase II study of oxaliplatin combined with 5-day infusion of 5-FU and LCV in advanced colorectal cancer preliminary data
    Janinis, J
    Efstathiou, E
    Aravantinos, G
    Samantas, E
    Tselepidakis, K
    Dervenis, E
    Skarlos, D
    ANNALS OF ONCOLOGY, 1998, 9 : 179 - 179
  • [46] Concomitant 5-FU, hydroxyurea and cisplatin with external beam radiation therapy for locally advanced pancreatic cancer: A phase II study
    Chen, LM
    Haraf, D
    Brachman, DG
    Vokes, EE
    Schilsky, RL
    ONCOLOGY REPORTS, 1997, 4 (05) : 877 - 881
  • [47] Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer
    Rao, S
    Cunningham, D
    Hawkins, RE
    Hill, ME
    Smith, D
    Daniel, F
    Ross, PJ
    Oates, J
    Norman, AR
    BRITISH JOURNAL OF CANCER, 2005, 92 (09) : 1650 - 1654
  • [48] FLOX regimen (5-FU, folinic acid, oxaliplatin) and FLIRI regimen (5-FU, folinic acid, irinotecan) as first-line treatment in metastatic and locally advanced gastric cancer: A randomized phase II study.
    Glenjen, Nils
    Hammerling, Katrin
    Hatlevoll, Ingunn
    Smaland, Rune
    Hauge, Petra Weber
    Eide, Geir Egil
    Sorbye, Halfdan
    Dahl, Olav
    Frykholm, Gunilla
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [49] Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer
    S Rao
    D Cunningham
    R E Hawkins
    M E Hill
    D Smith
    F Daniel
    P J Ross
    J Oates
    A R Norman
    British Journal of Cancer, 2005, 92 : 1650 - 1654
  • [50] A phase II randomized study of Combined Infusional Leucovorin Sodium and 5-FU versus the Leucovorin Calcium followed by 5-FU both in combination with Irinotecan or Oxaliplatin in patients with metastatic colorectal cancer
    Bleiberg, H.
    Vandebroek, A.
    Deleu, I.
    Vergauwe, P.
    Kalantari, H. Rezaei
    D'Haens, G.
    Paesmans, M.
    Peeters, M.
    Efira, A.
    Humblet, Y.
    ACTA GASTRO-ENTEROLOGICA BELGICA, 2012, 75 (01): : 14 - 21
12345